FDA Schedules Public Meeting on Paclitaxel Use in PAD


April 22, 2019—The FDA announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will convene a public meeting to discuss and make recommendations on information related to recent observations of increased long-term mortality in patients with peripheral arterial disease treated with paclitaxel-coated balloons and paclitaxel-eluting stents compared with patients treated with uncoated comparator devices.

The meeting, which will be open to the public, will be held on June 19 from 8:00 AM to 5:00 PM and June 20 from 8:00 AM to 3:00 PM at the Gaithersburg Holiday Inn in Gaithersburg, Maryland.

FDA requests panel input regarding the presence and magnitude of the signal and potential causes. FDA also seeks input regarding appropriate regulatory actions associated with the findings. The general function of the committee is to provide advice and recommendations to the agency on FDA's regulatory issues.

More information is available online, here. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before May 22, 2019.

For details regarding these data and all news related to the ongoing controversy regarding paclitaxel use in PAD, please visit our comprehensive continuing coverage page.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.